<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345058</url>
  </required_header>
  <id_info>
    <org_study_id>2010-P-001630</org_study_id>
    <nct_id>NCT01345058</nct_id>
  </id_info>
  <brief_title>Add on Lacosamide Versus High Dose Monotherapy</brief_title>
  <official_title>Open Label Trial of Add on Lacosamide Versus High Dose Monotherapy in Patients With a Seizure Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine whether a combination of low dose lacosamide and levetiracetam
      is more effective than high dose levetiracetam in patients who have failed low dose
      levetiracetam.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2011</start_date>
  <completion_date type="Actual">October 21, 2014</completion_date>
  <primary_completion_date type="Actual">February 15, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Six Month Seizure Freedom</measure>
    <time_frame>6 Months</time_frame>
    <description>Seizure freedom is defined as having no seizures and was evaluated in the 6 month period after receiving the drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seizure-Free Days</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Seizure After Therapeutic Dose is Reached</measure>
    <time_frame>6 Months</time_frame>
    <description>Time in days until the first seizure after the therapeutic dose is reached occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention Rate</measure>
    <time_frame>6 Months</time_frame>
    <description>Retention rate is defined as the percentage of participants who remained on the study drug after study completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAE)</measure>
    <time_frame>6 Months</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence (side effect) in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurs after receiving the drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Lacosamide + Low-Dose Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group (High-Dose Levetiracetam)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam &gt;1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lacosamide</intervention_name>
    <description>Lacosamide maximum of 200 mg/day, to be titrated as follows:
Week 1: 50 mg twice a day
Beginning Week 2: 100 mg twice a day.</description>
    <arm_group_label>Lacosamide + Low-Dose Levetiracetam</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levetiracetam</intervention_name>
    <description>Low dose ≤1500 mg/day, High dose &gt;1500 mg/day</description>
    <arm_group_label>Lacosamide + Low-Dose Levetiracetam</arm_group_label>
    <arm_group_label>Control Group (High-Dose Levetiracetam)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults age 18 or older

          2. Determined to have had at least two partial seizures by an epilepsy specialist, or to
             have had a single partial seizure with clinical and/or laboratory evidence of a high
             seizure recurrence risk

          3. Monotherapy on levetiracetam less than or equal to 1500 mg/day for at least two weeks

          4. Breakthrough seizure while on stable dose (&gt;5 days) of levetiracetam monotherapy
             regimen, not due to provocative factors (e.g. hypoglycemia, head trauma, missed
             medications)

        Exclusion Criteria:

          1. Clinical suspicion of nonepileptic psychogenic seizures or idiopathic generalized
             epilepsy

          2. Pregnant, child-bearing age not using contraception, or breast feeding

          3. Medical contraindication to adding lacosamide

          4. History of antiepileptic drug (AED) polytherapy

          5. Presence of a vagus nerve stimulator

          6. Creatinine clearance of less than 50 mL/min

          7. Blood pressure instability: pulse &lt;50 or &gt;100, systolic blood pressure (SBP) &lt;50 or
             &gt;180, clinically significant electrocardiogram (EKG) abnormality

          8. History of significant drug rash or anaphylactic reaction with antiepileptic drug

          9. Patients with progressive lesions (e.g. brain tumors)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Woo Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lee JW, Alam J, Llewellyn N, Hurwitz S, Bubrick EB, Sarkis RA, Weisholtz D, Yu H, Putta S, Dworetzky BA, Pennell PB. Open Label Trial of Add on Lacosamide Versus High Dose Levetiracetam Monotherapy in Patients With Breakthrough Seizures. Clin Neuropharmacol. 2016 May-Jun;39(3):128-31. doi: 10.1097/WNF.0000000000000144.</citation>
    <PMID>26992155</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <results_first_submitted>March 15, 2017</results_first_submitted>
  <results_first_submitted_qc>March 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jong Woo Lee</investigator_full_name>
    <investigator_title>Associate Neurologist</investigator_title>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>antiepileptic drug</keyword>
  <keyword>polytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Lacosamide</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lacosamide + Low-Dose Levetiracetam</title>
          <description>Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.</description>
        </group>
        <group group_id="P2">
          <title>Control Group (High-Dose Levetiracetam)</title>
          <description>Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam &gt;1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Lacosamide</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Reported Increase in Events</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Side Effects of Hair Loss and Itchiness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Stopped Taking Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant No-Show at Multiple Visits</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Lacosamide + Low-Dose Levetiracetam</title>
          <description>Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.</description>
        </group>
        <group group_id="B2">
          <title>Control Group (High-Dose Levetiracetam)</title>
          <description>Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam &gt;1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="17.5"/>
                    <measurement group_id="B2" value="43.7" spread="19.8"/>
                    <measurement group_id="B3" value="43.4" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Six Month Seizure Freedom</title>
        <description>Seizure freedom is defined as having no seizures and was evaluated in the 6 month period after receiving the drug.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide + Low-Dose Levetiracetam</title>
            <description>Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (High-Dose Levetiracetam)</title>
            <description>Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam &gt;1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Six Month Seizure Freedom</title>
          <description>Seizure freedom is defined as having no seizures and was evaluated in the 6 month period after receiving the drug.</description>
          <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
            <estimate_desc>Hazard ratio for seizure occurrence for polytherapy relative to monotherapy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seizure-Free Days</title>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide + Low-Dose Levetiracetam</title>
            <description>Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (High-Dose Levetiracetam)</title>
            <description>Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam &gt;1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seizure-Free Days</title>
          <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included in the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.11" spread="68.59"/>
                    <measurement group_id="O2" value="114.0" spread="65.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Seizure After Therapeutic Dose is Reached</title>
        <description>Time in days until the first seizure after the therapeutic dose is reached occurs.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide + Low-Dose Levetiracetam</title>
            <description>Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (High-Dose Levetiracetam)</title>
            <description>Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam &gt;1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Seizure After Therapeutic Dose is Reached</title>
          <description>Time in days until the first seizure after the therapeutic dose is reached occurs.</description>
          <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included in the analysis.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.0" lower_limit="9.0" upper_limit="180.0"/>
                    <measurement group_id="O2" value="116.5" lower_limit="6.0" upper_limit="180.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention Rate</title>
        <description>Retention rate is defined as the percentage of participants who remained on the study drug after study completion.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide + Low-Dose Levetiracetam</title>
            <description>Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (High-Dose Levetiracetam)</title>
            <description>Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam &gt;1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Retention Rate</title>
          <description>Retention rate is defined as the percentage of participants who remained on the study drug after study completion.</description>
          <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAE)</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence (side effect) in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurs after receiving the drug.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included. One participant never confirmed taking the study medication, never followed up, and was not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide + Low-Dose Levetiracetam</title>
            <description>Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (High-Dose Levetiracetam)</title>
            <description>Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam &gt;1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAE)</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence (side effect) in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurs after receiving the drug.</description>
          <population>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included. One participant never confirmed taking the study medication, never followed up, and was not included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Months</time_frame>
      <desc>All eligible participants. One participant in the Lacosamide + Low-Dose Levetiracetam arm did not receive study drug and is not included in the analysis. One participant never confirmed taking the study medication, never followed up, and was not included in the analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lacosamide + Low-Dose Levetiracetam</title>
          <description>Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.</description>
        </group>
        <group group_id="E2">
          <title>Control Group (High-Dose Levetiracetam)</title>
          <description>Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam &gt;1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability/depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Memory/cognitive difficulties/confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Decreased libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jong Woo Lee, MD, PhD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <email>JLEE38@BWH.HARVARD.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

